ChemDiv chemistry of cures

Prime Minister Outlines Initiative to Further Develop the Pharmaceutical Industry by 2020

The Russian government took a major step towards developing its pharmaceutical industry with an announcement made during a recent meeting at ChemRar Hi-Tech Center, a ChemDiv’s Research Facility located in Moscow, Russia. The meeting held with Prime Minister Vladimir Putin, Moscow Regional Governor Boris Gromov, the Minister of Health and Social Development Tatyana Golikova, the Minister of Industry and Trade Viktor Khristenko and company officials outlined the future development of the industry by the year 2020.

“We were excited to hold such a high profile strategic policy meeting with top government officials, heads of the leading pharmaceutical research institutes and directors of the major medical universities,” said Andrey Ivashchenko, Chairman of Board of Directors of the ChemRar Hi-Tech Center. “It really demonstrated the Russian Federation government’s commitment to long term development and investment in our industry.”

In announcing this major initiative, “The Strategy of Pharmaceutical Industry Development in the Russian Federation for the Period Up to the Year 2020,” Prime Minister Putin emphasized that the strategic goal of the program is to meet the pharmaceutical and medical devices needs of the Russian market by the year 2020.

The government’s ultimate plan is to achieve a 90 percent rate of domestically produced vital and essential drugs and a 50 percent rate of medical equipment production by a year of 2020. At the same time Russia will strengthen its position in international markets by drastically increasing imports of pharmaceutical products.

In the announcement, the government committed $6 billion towards kick starting the initiative. The allocation of funds will serve as a starting capital for industry modernization and initiate an innovative breakthrough in the pharmaceutical and biotech markets.

“The total investment under the federal program is $6 Billion, including $3.97 billion from the federal budget. I believe that the public funds should be applied towards initiation of vital research projects and technological upgrade of 160 enterprises,” said Putin. “…we will build a new industry that is attractive to investments and will generate innovation and create better jobs. And most importantly, it will supply competitive, safe, high-quality, and affordable products for the citizens and our public health.”

ChemDiv’s modern hi-tech development facility carries out a full cycle of preclinical and clinical development of new drugs and medical compounds, including developing finished dosage forms and producing novel drugs. Over the last two years, new formulas to treat diseases of the central nervous system (such as Alzheimer’s disease) and viral diseases (Hepatitis C) were developed on the company’s premises. In addition, a number of promising molecules in the field of oncology are now in late preclinical stage. For many years ChemRar Hi Tech Center has been serving as a leading partner in major government contracts for developing new drugs.

Prime Minister Putin endorsed ChemDiv’s Research Center international resources and noted, “They instantly collaborate with European partners by having established a close contact and cooperation.”

About ChemRar Hi-Tech Center

ChemRar Hi-Tech Center is a unique non-governmental research center and innovative business incubator in Russia with a group of ventures created under its roof. These life science research and development organizations discover, develop and commercialize novel drugs for pharmaceutical and biotech partners in Russia and worldwide.

The mission of the company is to develop and commercialize innovative drugs on the basis of recent “post-genomic” technologies, create new research opportunities for Pharma and Biotech partners, construct a framework for innovative or generic domestically developed and manufactured drugs, and establish integrated programs for localization of pharmaceutical development and production in Russia.

ChemRar Hi-Tech Center performs a full cycle of pre-clinical and clinical research of new drug candidates including identification of essential biological targets, biological screening, synthesis, chemical development, formulation and full cycle of drug production.

For more information about the company, please check the website at www.chemrar.ru

MEDIA CONTACT:

Oleg Korzinov
Director of Innovative Development
ChemRar Hi-Tech Center
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it